Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.

The high mortality rate of lung cancer patients is mainly due to the late stage at which lung cancer is diagnosed. For effective cancer prevention programs and early diagnosis, better blood-based markers are needed. Hence, blood-based microarray profiling of microRNA (miR) expression was performed i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carina Roth, Isabel Stückrath, Klaus Pantel, Jakob R Izbicki, Michael Tachezy, Heidi Schwarzenbach
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8817294352374baebb54d2d442fd81c8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8817294352374baebb54d2d442fd81c8
record_format	dspace
spelling	oai:doaj.org-article:8817294352374baebb54d2d442fd81c82021-11-18T07:16:28ZLow levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.1932-620310.1371/journal.pone.0038248https://doaj.org/article/8817294352374baebb54d2d442fd81c82012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22675530/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203The high mortality rate of lung cancer patients is mainly due to the late stage at which lung cancer is diagnosed. For effective cancer prevention programs and early diagnosis, better blood-based markers are needed. Hence, blood-based microarray profiling of microRNA (miR) expression was performed in preoperative serum of 21 non-small cell lung cancer (NSCLC) patients and 11 healthy individuals by microfluid biochips containing 1158 different miRs. Two out of the 30 most dysregulated miRs were further validated in serum of 97 NSCLC patients, 20 patients with benign lung diseases and 30 healthy individuals by TaqMan MicroRNA Assays. Microarray profiling showed that miR-361-3p and miR-625* were significantly down-regulated in serum of lung cancer patients. Their further evaluation by quantitative RT-PCR showed that the levels of miR-361-3p and miR-625* were lower in NSCLC than in benign disease (p = 0.0001) and healthy individuals (p = 0.0001, p = 0.0005, respectively). Moreover, the levels of miR-625* were significantly lower in patients with large cell lung cancer (LCLC, p = 0.014) and smoking patients (p = 0.030) than in patients with adenocarcinoma and non-smoking patients, respectively. A rise in the levels of both miRs was observed in the postoperative samples compared with the preoperative levels (p = 0.0001). Functional analyses showed that Smad2 and TGFß1 are not dysregulated by miR-361-3p and miR-625* in the lung cell line A549, respectively. Our present pilot study suggests that miR-361-3p and miR-625* might have a protective influence on the development of NSCLC, and the quantitative assessment of these miRs in blood serum might have diagnostic potential to detect NSCLC, in particular in smokers.Carina RothIsabel StückrathKlaus PantelJakob R IzbickiMichael TachezyHeidi SchwarzenbachPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 6, p e38248 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Carina Roth Isabel Stückrath Klaus Pantel Jakob R Izbicki Michael Tachezy Heidi Schwarzenbach Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.
description	The high mortality rate of lung cancer patients is mainly due to the late stage at which lung cancer is diagnosed. For effective cancer prevention programs and early diagnosis, better blood-based markers are needed. Hence, blood-based microarray profiling of microRNA (miR) expression was performed in preoperative serum of 21 non-small cell lung cancer (NSCLC) patients and 11 healthy individuals by microfluid biochips containing 1158 different miRs. Two out of the 30 most dysregulated miRs were further validated in serum of 97 NSCLC patients, 20 patients with benign lung diseases and 30 healthy individuals by TaqMan MicroRNA Assays. Microarray profiling showed that miR-361-3p and miR-625* were significantly down-regulated in serum of lung cancer patients. Their further evaluation by quantitative RT-PCR showed that the levels of miR-361-3p and miR-625* were lower in NSCLC than in benign disease (p = 0.0001) and healthy individuals (p = 0.0001, p = 0.0005, respectively). Moreover, the levels of miR-625* were significantly lower in patients with large cell lung cancer (LCLC, p = 0.014) and smoking patients (p = 0.030) than in patients with adenocarcinoma and non-smoking patients, respectively. A rise in the levels of both miRs was observed in the postoperative samples compared with the preoperative levels (p = 0.0001). Functional analyses showed that Smad2 and TGFß1 are not dysregulated by miR-361-3p and miR-625* in the lung cell line A549, respectively. Our present pilot study suggests that miR-361-3p and miR-625* might have a protective influence on the development of NSCLC, and the quantitative assessment of these miRs in blood serum might have diagnostic potential to detect NSCLC, in particular in smokers.
format	article
author	Carina Roth Isabel Stückrath Klaus Pantel Jakob R Izbicki Michael Tachezy Heidi Schwarzenbach
author_facet	Carina Roth Isabel Stückrath Klaus Pantel Jakob R Izbicki Michael Tachezy Heidi Schwarzenbach
author_sort	Carina Roth
title	Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.
title_short	Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.
title_full	Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.
title_fullStr	Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.
title_full_unstemmed	Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.
title_sort	low levels of cell-free circulating mir-361-3p and mir-625* as blood-based markers for discriminating malignant from benign lung tumors.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/8817294352374baebb54d2d442fd81c8
work_keys_str_mv	AT carinaroth lowlevelsofcellfreecirculatingmir3613pandmir625asbloodbasedmarkersfordiscriminatingmalignantfrombenignlungtumors AT isabelstuckrath lowlevelsofcellfreecirculatingmir3613pandmir625asbloodbasedmarkersfordiscriminatingmalignantfrombenignlungtumors AT klauspantel lowlevelsofcellfreecirculatingmir3613pandmir625asbloodbasedmarkersfordiscriminatingmalignantfrombenignlungtumors AT jakobrizbicki lowlevelsofcellfreecirculatingmir3613pandmir625asbloodbasedmarkersfordiscriminatingmalignantfrombenignlungtumors AT michaeltachezy lowlevelsofcellfreecirculatingmir3613pandmir625asbloodbasedmarkersfordiscriminatingmalignantfrombenignlungtumors AT heidischwarzenbach lowlevelsofcellfreecirculatingmir3613pandmir625asbloodbasedmarkersfordiscriminatingmalignantfrombenignlungtumors
_version_	1718423676582363136

Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.

Ejemplares similares